Literature DB >> 24502962

Lipoprotein (a), LPA Ile4399Met, and fibrin clot properties.

Charles M Rowland1, Clive R Pullinger2, May M Luke3, Dov Shiffman3, Lauri Green4, Irina Movsesyan5, James J Devlin3, Mary J Malloy5, John P Kane5, Anetta Undas6.   

Abstract

INTRODUCTION: Elevated lipoprotein(a) (Lp(a)) levels were reported to be associated with dense fibrin clots. The apo(a) component of Lp(a) is encoded by LPA, and the Met allele of the LPA Ile4399Met polymorphism is associated with elevated Lp(a) levels and cardiovascular disease risk. We investigated whether Ile4399Met was associated with fibrin clot properties.
MATERIALS AND METHODS: We determined plasma Lp(a) levels, fibrin clot permeability and lysis time for 64 LPA 4399Met carriers and 128 noncarriers matched for age, sex, ethnicity, and enrollment site.
RESULTS: Elevated Lp(a) levels were associated with reduced clot permeability and prolonged lysis time (P<0.0001). Carriers of 4399Met had higher Lp(a) levels compared with noncarriers (P=0.0003). However, this association differed by ethnicity (P=0.003 for interaction between genotype and ethnicity): compared with noncarriers, 4399Met carriers had 2.89 fold higher Lp(a) levels among Caucasians while no difference was observed among non-Caucasians (primarily East Asians and Hispanics). Among all subjects, no association was observed between Ile4399Met and clot properties, but this relationship also differed by ethnicity: among non-Caucasians, 4399Met carriers had increased clot permeability and shorter lysis time; whereas among Caucasians, the trend was for decreased permeability and longer lysis time (P<0.01 for interactions between genotype and ethnicity).
CONCLUSIONS: We confirmed that elevated Lp(a) levels are associated with dense fibrin clots, and found that the association of LPA 4399Met carriers and clot permeability as well as lysis time differ by ethnicity.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Lipoprotein(a); fibrin clot; genetics; polymorphism; thrombosis

Mesh:

Substances:

Year:  2014        PMID: 24502962     DOI: 10.1016/j.thromres.2014.01.024

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  8 in total

1.  Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis.

Authors:  Michael B Boffa; Tanya T Marar; Calvin Yeang; Nicholas J Viney; Shuting Xia; Joseph L Witztum; Marlys L Koschinsky; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2019-09-24       Impact factor: 5.922

Review 2.  Structure, function, and genetics of lipoprotein (a).

Authors:  Konrad Schmidt; Asma Noureen; Florian Kronenberg; Gerd Utermann
Journal:  J Lipid Res       Date:  2016-04-13       Impact factor: 5.922

Review 3.  Lipoprotein(a) beyond the kringle IV repeat polymorphism: The complexity of genetic variation in the LPA gene.

Authors:  Stefan Coassin; Florian Kronenberg
Journal:  Atherosclerosis       Date:  2022-05       Impact factor: 6.847

Review 4.  Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?

Authors:  Michael B Boffa; Marlys L Koschinsky
Journal:  J Lipid Res       Date:  2015-12-08       Impact factor: 5.922

Review 5.  Lipoprotein(a) and Arterial Stiffness Parameters.

Authors:  Alexander Sorokin; Kazuhiko Kotani
Journal:  Pulse (Basel)       Date:  2015-08-25

6.  Effect of Two Lipoprotein (a)-Associated Genetic Variants on Plasminogen Levels and Fibrinolysis.

Authors:  Hong Wang; Chan E Hong; Joshua P Lewis; Yanbei Zhu; Xing Wang; Xin Chu; Joshua Backman; Ziying Hu; Peixin Yang; Christopher D Still; Glenn S Gerhard; Mao Fu
Journal:  G3 (Bethesda)       Date:  2016-11-08       Impact factor: 3.154

Review 7.  The role of novel atherosclerosis markers in peripheral artery disease: is there a gender difference?

Authors:  Hora Iu Comşa; Dumitru Zdrenghea; Sorin Claudiu Man; Dana Pop
Journal:  Cardiovasc J Afr       Date:  2018-04-20       Impact factor: 1.167

Review 8.  Lipoprotein(a)-The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation.

Authors:  Sabina Ugovšek; Miran Šebeštjen
Journal:  Biomolecules       Date:  2021-12-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.